[go: up one dir, main page]

PE20181156A1 - Genes de ataxia de friedreich modificados y vectores para terapia genica - Google Patents

Genes de ataxia de friedreich modificados y vectores para terapia genica

Info

Publication number
PE20181156A1
PE20181156A1 PE2018000726A PE2018000726A PE20181156A1 PE 20181156 A1 PE20181156 A1 PE 20181156A1 PE 2018000726 A PE2018000726 A PE 2018000726A PE 2018000726 A PE2018000726 A PE 2018000726A PE 20181156 A1 PE20181156 A1 PE 20181156A1
Authority
PE
Peru
Prior art keywords
vectors
gene therapy
friedreich ataxia
modified
ataxia genes
Prior art date
Application number
PE2018000726A
Other languages
English (en)
Inventor
Richard J Samulski
Original Assignee
Bamboo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bamboo Therapeutics Inc filed Critical Bamboo Therapeutics Inc
Publication of PE20181156A1 publication Critical patent/PE20181156A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)

Abstract

La presente invencion se relaciona con un gen modificado de FXN que proporciona una expresion incrementada de la proteina de frataxina codificada que puede utilizarse para el tratamiento de la ataxia de Friedreich
PE2018000726A 2015-11-05 2016-11-01 Genes de ataxia de friedreich modificados y vectores para terapia genica PE20181156A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562251288P 2015-11-05 2015-11-05
US201662411980P 2016-10-24 2016-10-24

Publications (1)

Publication Number Publication Date
PE20181156A1 true PE20181156A1 (es) 2018-07-19

Family

ID=57288476

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000726A PE20181156A1 (es) 2015-11-05 2016-11-01 Genes de ataxia de friedreich modificados y vectores para terapia genica

Country Status (18)

Country Link
US (2) US10548947B2 (es)
EP (1) EP3370778A1 (es)
JP (2) JP6767483B2 (es)
KR (2) KR102200642B1 (es)
CN (1) CN108348621A (es)
AU (2) AU2016347887B2 (es)
BR (1) BR112018007453A2 (es)
CA (1) CA2947584A1 (es)
CO (1) CO2018004564A2 (es)
HK (1) HK1250924A1 (es)
IL (1) IL259141A (es)
MX (1) MX2018005084A (es)
PE (1) PE20181156A1 (es)
PH (1) PH12018500964A1 (es)
RU (2) RU2743792C2 (es)
SG (2) SG11201802408RA (es)
TW (2) TWI654301B (es)
WO (1) WO2017077451A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10617770B2 (en) * 2015-04-24 2020-04-14 University Of Florida Research Foundation, Incorporated AAV vector for treatment of Friedreich's ataxia
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
RU2726131C2 (ru) 2015-05-22 2020-07-09 Дмитрий Дмитриевич Генкин Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
MX2018005084A (es) * 2015-11-05 2019-05-16 Bamboo Therapeutics Inc Genes de ataxia de friedreich modificados y vectores para terapia genica.
CN116059245A (zh) 2016-03-23 2023-05-05 加利福尼亚大学董事会 治疗线粒体障碍的方法
US12011488B2 (en) 2016-03-23 2024-06-18 The Regents Of The University Of California Methods of treating mitochondrial disorders
EP3491440A4 (en) 2016-09-21 2020-02-26 Commscope Technologies LLC ADAPTER BLOCK ASSEMBLY
EP3538660A1 (en) 2016-11-09 2019-09-18 Intrexon Corporation Frataxin expression constructs
EP3687582A4 (en) 2017-09-29 2021-07-14 Voyager Therapeutics, Inc. RESCUE OF CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE OF FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
US11993790B2 (en) 2017-10-03 2024-05-28 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
BR112020006671A2 (pt) 2017-10-03 2020-12-01 Prevail Therapeutics, Inc. terapias genéticas para distúrbios lisossômicos
WO2019070893A1 (en) 2017-10-03 2019-04-11 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISORDERS
EP4089173A1 (en) * 2017-10-17 2022-11-16 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Vectors for the treatment of friedreich's ataxia
KR20200122320A (ko) 2018-01-16 2020-10-27 씨엘에스 테라퓨틱스 리미티드 데옥시리보뉴클레아제 (dnase) 활성을 갖는 효소의 간 발현에 의한 질환의 치료
MX2020010464A (es) 2018-04-03 2021-01-29 Vectores de virus que evitan anticuerpos.
SG11202009450SA (en) 2018-04-03 2020-10-29 Stridebio Inc Virus vectors for targeting ophthalmic tissues
WO2019195444A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
JP2021532832A (ja) * 2018-08-02 2021-12-02 ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. フリートライヒ運動失調症を処置するための筋標的化複合体およびそれらの使用
WO2020028864A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
EP3833755A4 (en) * 2018-08-10 2022-05-25 Logicbio Therapeutics, Inc. DISRUPTIVE GENE THERAPY FOR THE TREATMENT OF MMA
JP7528066B2 (ja) * 2018-09-28 2024-08-05 ボイジャー セラピューティクス インコーポレイテッド 操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法
CN113613633A (zh) * 2018-11-14 2021-11-05 旗舰先锋创新V股份有限公司 用于cns递送的融合剂脂质体组合物
EP3880823A4 (en) * 2018-11-16 2022-08-17 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus for treating pompe disease
TW202039533A (zh) * 2018-11-21 2020-11-01 美商史崔德生物公司 重組病毒載體及用於生產其之核酸
AU2019406214A1 (en) * 2018-12-21 2021-08-05 Northwestern University Use of annexins in preventing and treating muscle membrane injury
MX2021011468A (es) 2019-03-21 2021-12-15 Vectores de virus adenoasociados recombinantes.
MX2021011824A (es) * 2019-03-27 2021-12-10 Sigilon Therapeutics Inc Composiciones, dispositivos y metodos para la terapia del factor vii.
WO2020198641A2 (en) * 2019-03-28 2020-10-01 Intellia Therapeutics, Inc. Polynucleotides, compositions, and methods for polypeptide expression
KR20220006527A (ko) 2019-04-10 2022-01-17 프리베일 테라퓨틱스, 인크. 리소좀 장애에 대한 유전자 요법
US20230144548A1 (en) * 2019-06-30 2023-05-11 John Fraser Wright Recombinant aav vectors with altered immunogencity and methods of making the same
EP3999120A4 (en) * 2019-07-04 2024-02-21 Children's Medical Research Institute Methods and aav vectors for in vivo transduction
CA3147034A1 (en) * 2019-07-12 2021-01-21 Cls Therapeutics Limited Treatment of diseases associated with protein misfolding by nervous system expression of an enzyme which has a deoxyribonuclease (dnase) activity
US20220211737A1 (en) * 2019-09-13 2022-07-07 Lacerta Therapeutics, Inc. Compositions and methods for treatment of friedreichs ataxia
EP4045525A1 (en) 2019-10-17 2022-08-24 Stridebio, Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
AU2020405149A1 (en) * 2019-12-19 2022-07-07 The Trustees Of The University Of Pennsylvania Compositions for treating Friedreich's ataxia
CN113755524B (zh) * 2020-06-02 2023-11-03 舒泰神（北京）生物制药股份有限公司 用于治疗脊髓性肌萎缩的腺相关病毒载体及其用途
EP4188404A4 (en) * 2020-07-29 2025-02-26 The Board Of Regents Of The University Of Texas System TRANSGENIC CASSETTES, AAV VECTORS AND AAV VIRUS VECTORS FOR THE EXPRESSION OF HUMAN CODON-OPTIMIZED CSTB
CA3189878A1 (en) 2020-08-19 2022-02-24 Colin O'BANION Adeno-associated virus vectors for treatment of rett syndrome
AU2021375404A1 (en) 2020-11-03 2023-06-08 Pfizer Inc. Methods for purification of aav vectors by anion exchange chromatography
EP4267726A1 (en) 2020-12-23 2023-11-01 Pfizer Inc. Methods for purification of aav vectors by affinity chromatography
CA3207161A1 (en) * 2021-01-04 2022-07-07 University Of Florida Research Foundation, Incorporated Methods and compositions for treatment of friedreich's ataxia
US20240050521A1 (en) * 2021-01-11 2024-02-15 The Trustees Of The University Of Pennsylvania Compositions for treating friedreich's ataxia
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
WO2023114816A1 (en) 2021-12-14 2023-06-22 Neurogene, Inc. Recombinant optimized galc constructs and methods for treating galc-associated disorders
GB202201242D0 (en) 2022-01-31 2022-03-16 Univ Edinburgh Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
GB202206336D0 (en) 2022-04-29 2022-06-15 Univ Edinburgh Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
WO2024003687A1 (en) 2022-06-28 2024-01-04 Pfizer Inc. Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
EP4551596A2 (en) * 2022-07-06 2025-05-14 Adverum Biotechnologies, Inc. Compositions and methods for treatment of achromotopsia
CN116121350A (zh) * 2022-12-02 2023-05-16 百码科技(深圳)有限公司 一种检测fxn致病基因突变的方法
CN117089514A (zh) * 2023-10-13 2023-11-21 思鹏生物科技(苏州)有限公司 提升hek293细胞系aav生产效率的细胞筛选驯化方法
WO2026017965A1 (en) 2024-07-19 2026-01-22 The University Court Of The University Of Edinburgh Recombinant therapeutic fxn constructs and methods of treating friedreich ataxia and related conditions

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
AU707862B2 (en) 1995-06-07 1999-07-22 University Of North Carolina At Chapel Hill, The Helper virus-free aav production
AU723497C (en) 1996-09-06 2001-10-11 Trustees Of The University Of Pennsylvania, The Method for recombinant adeno-associated virus-directed gene therapy
US20030215422A1 (en) 1996-09-11 2003-11-20 John A. Chiorini Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
ES2313784T3 (es) 1998-05-28 2009-03-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Vector aav5 y usos del mismo.
AU768729B2 (en) 1998-11-05 2004-01-08 Trustees Of The University Of Pennsylvania, The Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
WO2000028004A1 (en) 1998-11-10 2000-05-18 The University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
NZ522840A (en) 2000-06-01 2004-12-24 Univ North Carolina A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
WO2002046359A2 (en) 2000-12-07 2002-06-13 Universite De Nantes Inducible highly productive raav packaging cell-lines
DK2292779T3 (en) 2003-09-30 2017-02-27 Univ Pennsylvania ADENOASS-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME AND APPLICATIONS THEREOF
AU2005316476A1 (en) 2004-12-15 2006-06-22 University Of Florida Research Foundation, Inc. Chimeric vectors
DK3216802T3 (da) * 2007-08-20 2021-01-04 Glaxo Group Ltd Produktionsfremgangsmåde
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
AU2010340358B2 (en) * 2009-12-21 2014-07-24 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
WO2011097640A1 (en) * 2010-02-08 2011-08-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
EP2394667A1 (en) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
EP2718439B1 (en) * 2011-06-09 2017-08-09 CuRNA, Inc. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
CN104520421B (zh) 2011-10-28 2017-05-24 北卡罗来纳-查佩尔山大学 用于生产腺伴随病毒的细胞系
US9066966B2 (en) 2013-02-01 2015-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
IL293294B2 (en) 2013-03-15 2023-04-01 Univ North Carolina Chapel Hill Methods and compounds for ligation of paired aav glycan vectors
US11427835B2 (en) 2013-03-15 2022-08-30 The Children's Hospital Of Philadelphia Vectors comprising stuffer/filler polynucleotide sequences and methods of use
CA2907799A1 (en) 2013-05-31 2014-12-04 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
JP2016525347A (ja) 2013-07-12 2016-08-25 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ Ａａｖベクター、及び抗ａａｖ（アデノ関連ウイルス）中和抗体についてのアッセイ
CN105579465B (zh) 2013-07-22 2019-09-10 费城儿童医院 用于基因转移到细胞、器官和组织中的变异aav和组合物、方法及用途
EP3060575B1 (en) 2013-10-11 2018-12-05 Massachusetts Eye & Ear Infirmary Methods of predicting ancestral virus sequences and uses thereof
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
MX2018005084A (es) * 2015-11-05 2019-05-16 Bamboo Therapeutics Inc Genes de ataxia de friedreich modificados y vectores para terapia genica.

Also Published As

Publication number Publication date
AU2016347887A1 (en) 2018-04-19
BR112018007453A2 (pt) 2018-10-23
RU2743792C2 (ru) 2021-02-26
AU2016347887B2 (en) 2019-11-14
CO2018004564A2 (es) 2018-12-14
SG10201912763QA (en) 2020-02-27
RU2018116076A3 (es) 2020-08-21
EP3370778A1 (en) 2018-09-12
JP2021019591A (ja) 2021-02-18
CA2947584A1 (en) 2017-05-05
JP6767483B2 (ja) 2020-10-14
TW201920673A (zh) 2019-06-01
KR20180077275A (ko) 2018-07-06
MX2018005084A (es) 2019-05-16
US20170128528A1 (en) 2017-05-11
PH12018500964A1 (en) 2018-11-12
TWI654301B (zh) 2019-03-21
AU2020200976B2 (en) 2021-09-30
AU2020200976A1 (en) 2020-02-27
JP2018531609A (ja) 2018-11-01
WO2017077451A1 (en) 2017-05-11
HK1250924A1 (zh) 2019-01-18
TWI743442B (zh) 2021-10-21
CN108348621A (zh) 2018-07-31
TW201723179A (zh) 2017-07-01
RU2021102893A (ru) 2021-03-03
US10548947B2 (en) 2020-02-04
KR102200642B1 (ko) 2021-01-12
US20200384073A1 (en) 2020-12-10
KR20210005994A (ko) 2021-01-15
SG11201802408RA (en) 2018-05-30
IL259141A (en) 2018-06-28
RU2018116076A (ru) 2019-10-28

Similar Documents

Publication Publication Date Title
PE20181156A1 (es) Genes de ataxia de friedreich modificados y vectores para terapia genica
PH12019502724A1 (en) Compositions for modulating c9orf72 expression
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
CO2018012096A2 (es) Proteínas de fusión gdf15 y usos de estas
MA40902B1 (fr) Vaccins hpv16 thérapeutiques
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
BR112017001242A2 (pt) tratamento de câncer usando um receptor antigênico quimérico a cd33
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
CY1123623T1 (el) Θεραπεια νευρολογικων νοσων
MX2021006945A (es) Anelosomas para suministrar modalidades terapéuticas de reemplazo de proteínas.
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
BR112017000932A2 (pt) genes da protease de tabaco
CR20170197A (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidópteros
IL257260A (en) Motile sperm domain containing protein 2 and cancer
MX2017011794A (es) Composiciones y metodos para diagnosticos y tratamiento del cancer.
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
BR112018070255A2 (pt) reprogramação cardíaca direta melhorada.
SA519401756B1 (ar) أجزاء منشأة للتعبير الوراثي عن رنح فريدريك
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX386989B (es) Agente estimulador del receptor 5-hidroxitriptamina 1b para reparación de piel y/o cabello.